相似文献
1
Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.
J Am Heart Assoc. 2018 Nov 20;7(22):e010854. doi: 10.1161/JAHA.118.010854.
2
Anticoagulants: What is new and what is the standard?
Clin Pharmacol Ther. 2016 Aug;100(2):126-8. doi: 10.1002/cpt.400. Epub 2016 Jun 24.
3
Using new oral anticoagulants in patients undergoing major orthopedic surgery.
Curr Rheumatol Rep. 2015 Apr;17(4):25. doi: 10.1007/s11926-015-0498-z.
4
[Not Available].
Lakartidningen. 2018 Dec 4;115:FAXZ.
5
A Review on the New and Old Anticoagulants.
Orthop Nurs. 2019 Jan/Feb;38(1):53-54. doi: 10.1097/NOR.0000000000000533.
6
[Not Available].
Lakartidningen. 2018 Dec 4;115:FAS3.
7
Direct oral anticoagulants: An update.
Med Clin (Barc). 2018 Sep 14;151(5):198-206. doi: 10.1016/j.medcli.2017.11.042. Epub 2017 Dec 30.
8
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
J Thromb Haemost. 2018 Sep;16(9):1891-1894. doi: 10.1111/jth.14219. Epub 2018 Jul 19.
9
Measuring Direct Oral Anticoagulants.
Methods Mol Biol. 2017;1646:217-225. doi: 10.1007/978-1-4939-7196-1_18.
10
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Intern Emerg Med. 2017 Aug;12(5):561-563. doi: 10.1007/s11739-017-1688-7. Epub 2017 Jun 24.
引用本文的文献
1
Effectiveness of Transesophageal Echocardiography in Preventing Thromboembolic Complications Before Cardioversion: A Narrative Review.
Cureus. 2023 Nov 2;15(11):e48149. doi: 10.7759/cureus.48149. eCollection 2023 Nov.
2
Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (O'CAFÉ trial).
Trials. 2023 Mar 31;24(1):246. doi: 10.1186/s13063-023-07230-2.
3
Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (Pressure-AF).
Open Heart. 2021 Sep;8(2). doi: 10.1136/openhrt-2021-001739.
4
Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?
Medicina (Kaunas). 2021 May 31;57(6):554. doi: 10.3390/medicina57060554.
本文引用的文献
1
Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study.
Europace. 2018 Dec 1;20(12):1936-1943. doi: 10.1093/europace/euy141.
2
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148.
3
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion.
Europace. 2018 Apr 1;20(4):565-568. doi: 10.1093/europace/eux116.
4
Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.
Europace. 2018 Jun 1;20(6):e87-e95. doi: 10.1093/europace/eux127.
5
Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion.
Pol Arch Intern Med. 2017 Dec 22;127(12):823-831. doi: 10.20452/pamw.4117. Epub 2017 Sep 30.
6
Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
Heart Lung Circ. 2018 Jul;27(7):798-803. doi: 10.1016/j.hlc.2017.06.726. Epub 2017 Jul 17.
7
Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre.
Ir J Med Sci. 2017 Aug;186(3):615-620. doi: 10.1007/s11845-017-1582-3. Epub 2017 Feb 24.
8
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.
Circulation. 2017 Mar 7;135(10):e604-e633. doi: 10.1161/CIR.0000000000000477. Epub 2017 Feb 6.
9
Edoxaban: A direct oral anticoagulant.
Am J Health Syst Pharm. 2017 Feb 1;74(3):117-129. doi: 10.2146/ajhp150821.
10
A Comparison Between Dabigatran and Warfarin on Time to Elective Cardioversion.
J Atr Fibrillation. 2016 Apr 30;8(6):1355. doi: 10.4022/jafib.1355. eCollection 2016 Apr-May.
Zotero 插件